Status:
COMPLETED
Hematologic Profile, Vit. B12 and Folic Acid in Cirrhotics Received Sofosbuvir and Daclatasvir With or Without Ribavirin
Lead Sponsor:
Assiut University
Conditions:
Liver Cirrhoses
Chronic Hepatitis c
Eligibility:
All Genders
18-70 years
Brief Summary
Use of Ribavirin could affect hematologic profile of the patients negatively. With advent of new antiviral therapy, the preexisting hematologic changes may alter or corrected after treatment. However,...
Detailed Description
Hepatitis C virus (HCV) infection is a global health problem that affects 170 million people worldwide, and approximately 55% (95 million) of the infected population is in South East Asia and Western ...
Eligibility Criteria
Inclusion
- Patients known to have HCV-related liver cirrhosis and candidate for therapy with Sofosbuvir and Daclatasvir with or without Ribavirin
Exclusion
- Chronic hepatitis due causes other than chronic HCV infection
- Coinfection with HIV or HBV infection
- Hepatocellular carcinoma
- Decompensated cirrhosis
Key Trial Info
Start Date :
March 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 14 2020
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03283176
Start Date
March 1 2018
End Date
January 14 2020
Last Update
October 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mohamed Shaban Redwan Helal
Asyut, Egypt, 71111